Research Lab Review

Retatrutide outside trials: what new reports say about side effects

News · Retatrutide

A case report, a social-media survey and recent reviews outline what is known about retatrutide's side effects while large safety trials are still running.

Retatrutide is an investigational drug that has not been approved anywhere, but it is already being injected outside clinical trials. A 2026 case report describes a young woman hospitalised with severe nausea after injections of an unverified product said to contain it, and a new study looks at side effects reported by social media users [1, 2]. Meanwhile, the large trial designed to show whether retatrutide is safe for the heart and kidneys over the long term has no results yet [6].

Key takeaways

  • A single case report links injections of an unverified product reported to contain retatrutide to five days of persistent nausea and vomiting that did not respond to standard anti-nausea drugs; a standard causality scale rated the link “probable” [1].
  • A 2026 study in JAMA Network Open examined self-reported adverse effects among social media users taking nonapproved retatrutide; its abstract was not available to us, so we cannot report its findings [2].
  • Reviews point to gastrointestinal effects, hair shedding linked to rapid weight loss, and dysesthesia (abnormal skin sensations) seen in retatrutide trials as side effects that need closer study [3, 4, 5].
  • A phase 3 cardiovascular and kidney outcomes trial in adults with obesity is active but no longer recruiting, and has not reported results [6].

What retatrutide is

Retatrutide is a once-weekly peptide that acts on three hormone receptors at once: GLP-1, GIP and glucagon [4]. Older drugs in this family act on GLP-1 alone, and some newer ones act on GLP-1 and GIP; adding the glucagon receptor is the distinctive part of retatrutide’s design [4, 5]. According to one review, the glucagon component is of interest because it increases basal energy expenditure, a pathway that single and dual agonists do not engage [4].

In a phase 2 obesity trial, retatrutide produced a mean body-weight reduction of 24.2% at 48 weeks under the trial’s efficacy estimand [4]. The same review notes that company-reported phase 3 results from four trials, which have not yet been peer-reviewed, describe larger reductions [4]. Those phase 3 figures should be treated with caution until they are published in full.

A case report: nausea that standard drugs did not stop

The newest clinical report is a single case published in BMJ Case Reports [1]. A woman in her mid-20s arrived at hospital with five days of persistent nausea, repeated vomiting, loose stools and markedly reduced eating and drinking [1]. Blood tests, urine tests, abdominal ultrasound and a brain MRI found no other explanation [1].

Her symptoms continued despite intravenous fluids and three different anti-nausea drugs (metoclopramide, ondansetron and domperidone) [1]. Only after repeated, non-judgemental questioning did she mention a series of injections over the preceding weeks of an unverified product reported to contain retatrutide [1]. The injections had been given in a wellness setting by a self-described life coach with no medical qualification, and she did not think of them as medication [1].

Her symptoms improved two days after admission and cleared within a week [1]. The authors scored the case 7 on the Naranjo scale, a standard tool for judging whether a drug likely caused an adverse reaction, which corresponds to “probable” causality [1].

Limits. This is one person (n = 1). The product was never verified, so it is not known whether it contained retatrutide, how much, or what else it contained [1]. A case report can raise a signal but cannot show how common a reaction is. The authors’ main point is practical: substances from the wellness industry may not show up in a routine medication history, so clinicians should ask directly about injections, peptides, research chemicals and online products [1].

Social media reports of side effects

A 2026 study in JAMA Network Open looked at self-reported adverse effects among social media users taking nonapproved retatrutide [2]. No abstract was available in the record we were given, so we cannot describe its methods, sample size or results.

What can be said is how this type of study works in general. Self-reports from social media can show what people outside trials are experiencing and talking about, but they are usually not verified, the substance itself is usually untested, and people with strong experiences may be more likely to post. Such data describe reports, not confirmed rates.

What reviews say about side effects

Gastrointestinal effects. A 2026 review of GLP-1 receptor biology and incretin-based drugs lists gastrointestinal side effects among the main ongoing challenges for this drug class, along with weight regain after stopping, loss of lean body mass, and unresolved questions about long-term safety [5]. This is a broad review of the class rather than a study of retatrutide specifically [5].

Hair loss. A narrative review based on PubMed searches pulled together data from trials, real-world studies and pharmacovigilance databases on hair loss with semaglutide, tirzepatide and retatrutide [3]. It found a wide gap in reported rates: about 3% to 7% in controlled trials versus more than 70% in some real-world cohorts [3]. The main pattern was telogen effluvium, a usually temporary shedding that the authors link mainly to how much and how fast weight is lost, rather than to direct drug toxicity [3]. Female sex and weight loss above 10% were the strongest predictors [3]. The abstract does not give retatrutide-specific figures, and a narrative review does not use the systematic methods of a meta-analysis, so its conclusions are a summary rather than a pooled estimate [3].

Dysesthesia and use in specific groups. A 2026 narrative review considering retatrutide for people with schizophrenia spectrum disorders on clozapine or olanzapine notes that dysesthesia was observed in retatrutide trials and was dose-related in most but not all of them [4]. The authors stress that no trial has tested retatrutide in people taking antipsychotics [4]. They flag gastrointestinal tolerability, possible interaction with clozapine-related slowing of gut movement, and possible effects on blood levels of these antipsychotics as questions that would need dedicated trials [4]. Their ideas about energy expenditure are explicitly presented as an untested hypothesis [4].

The outcome trial still under way

TRIUMPH-Outcomes is a phase 3 trial testing once-weekly retatrutide on cardiovascular and kidney outcomes in adults living with obesity [6]. Its registry entry lists it as active but not recruiting, with the record last updated on 8 October 2026 [6]. A registry entry describes a trial’s plan, not its findings [6]. Trials of this kind are designed to detect less common or slower-developing harms and benefits that shorter weight-loss trials may miss.

What we still don’t know

  • Long-term safety. Reviews describe long-term safety for incretin-based drugs as an open question, and retatrutide’s outcome trial has not reported [5, 6].
  • What is in unverified products. In the case report, the contents of the injected product were never confirmed, so the reaction cannot be firmly tied to retatrutide itself [1].
  • How often side effects occur outside trials. One case and self-reported social media data cannot give reliable rates [1, 2].
  • Retatrutide-specific hair loss data. The hair loss review covers several drugs, and its abstract does not separate out retatrutide figures [3].
  • Specific populations. No trial has studied retatrutide in people taking clozapine or olanzapine [4].
  • Peer-reviewed phase 3 data. Phase 3 results described so far are company-reported and not yet peer-reviewed [4].

References

  1. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide. BMJ Case Reports (2026). doi:10.1136/bcr-2026-276106
  2. Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide. JAMA Network Open (2026). doi:10.1001/jamanetworkopen.2026.38929
  3. GLP-1 receptor agonists and hair loss: adverse effect, epiphenomenon, or therapeutic paradox?. Acta Diabetologica (2026). doi:10.1007/s00592-026-02812-3
  4. Potential Role of the Triple Receptor Agonist Retatrutide in Antipsychotic-Associated Metabolic Dysfunction Among Clozapine- and Olanzapine-Treated Schizophrenia Spectrum Disorders: A Narrative Review and Theoretical Framework. Biomedicines (2026). doi:10.3390/biomedicines14091957
  5. GLP-1 receptor biology and the therapeutic role of incretin-based agonists in metabolic diseases. European Journal of Pharmacology (2026). doi:10.1016/j.ejphar.2026.179406
  6. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes). ClinicalTrials.gov NCT06383390, status: active not recruiting.

Image credits

Free to use (CC0 / public domain); credited as a courtesy.

  • Exocrine and Endocrine Pancreas by Phase Contrast (32782209957).jpg, by Berkshire Community College Bioscience Image Library (CC0, via wikimedia-commons): source
Open the hub